Clinical features and outcomes of inpatients
with neurological disease and COVID-19

Alberto Benussi[1,2], MD, Andrea Pilotto[1,2], MD, Enrico Premi[3], MD, Ilenia Libri[1], MD, Marcello Giunta[1], MD, Chiara Agosti,[2] MD, Antonella Alberici,[2] MD, Enrico Baldelli,[1] MD, Matteo Benini, MD[4], Sonia Bonacina, MD,[1] Laura Brambilla,[5] MD, Salvatore Caratozzolo, MD,[2] Matteo Cortinovis,[1] MD, Angelo Costa,[3] MD, Stefano Cotti Piccinelli,[1] MD, Elisabetta Cottini,[2] MD, Viviana Cristillo,[1] MD, Ilenia Delrio,[3] MD, Massimiliano Filosto,[2] MD, Massimo Gamba,[3] MD, Stefano Gazzina,[6] MD, Nicola Gilberti, MD,[3] Stefano Gipponi, MD,[2] Alberto Imarisio,[1] MD, Paolo Invernizzi, MD,[7] Ugo Leggio,[6] MD, Matilde Leonardi, MD,[8] Paolo Liberini,[2] MD, Martina Locatelli,[1] MD, Stefano Masciocchi,[1] MD, Loris Poli,[2] MD, Renata Rao,[2] MD, Barbara Risi,[1] MD, Luca Rozzini,[1,2] MD, Andrea Scalvini,[1] MD, Francesca Schiano di Cola,[1] MD, Raffaella Spezi,[3] MD, Veronica Vergani,[3] MD, Irene Volonghi,[2] MD, Nicola Zoppi,[1] MD, Barbara Borroni,[1,2] MD, Mauro Magoni,[3] MD, Alessandro Pezzini,[1,2] MD, Alessandro Padovani,[1,2] MD, PhD

[1]*Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy*

[2]*Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy*

[3]*Vascular Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy*

[4]*Neurology Unit, University of Bologna, Bologna, Italy*

[5]*Department of Neuroimmunology and Neuromuscular Diseases, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy*

[6]*Neurophysiology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili di Brescia, Brescia, Italy*

[7]*Neurology Unit, Fondazione Poliambulanza Hospital, Brescia, Italy*

[8]*Neurology, Public Health and Disability Unit, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy*

*Corresponding author:

Alessandro Padovani, MD, PhD

Clinica Neurologica, Università degli Studi di Brescia

P.le Spedali Civili 1, 25123, Brescia, Italy

Phone: 0039 0303995632

Email: alessandro.padovani@unibs.it

Abstract

Objective: To report the clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurological diseases with COVID-19 in a Neuro-COVID unit compared to patients without COVID-19.

Methods: In this retrospective, single centre cohort study, we included all adult inpatients with confirmed COVID-19, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records.

Results: 173 patients were included in this study, of whom 56 resulted positive for COVID-19 and 117 resulted negative for COVID-19. Patients with COVID-19 were older, had a different distribution regarding admission diagnoses, including cerebrovascular disorders, and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (all $p<0.05$). In-hospital mortality rates and incident delirium were significantly higher in the COVID-19 group (all $p<0.05$). COVID-19 and non-COVID patients with stroke had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge ($p<0.0001$), with a significantly lower number of patients with a good outcome ($p<0.0001$).

Multivariable regressions showed increasing odds of in-hospital death associated with higher qSOFA scores (odds ratio 4.47, 95% CI 1.21-16.5; $p=0.025$), lower platelet count (0.98, 0.97-0.99; $p=0.005$) and higher lactate dehydrogenase (1.01, 1.00-1.03; $p=0.009$) on admission.

Conclusions: COVID-19 patients admitted with neurological disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19.

Introduction

Since February 20, 2020, Lombardy, Italy, has experienced a major outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with more than 50,000 cases and 9,000 deaths in the region as of April 5, 2020.[1]

The clinical spectrum of SAR-CoV-2 appears to be wide, encompassing asymptomatic infections, mild upper respiratory tract illness and severe pneumonia with respiratory failure and death.[2] Several factors have been associated with increased mortality, as older age, high Sequential Organ Failure Assessment (SOFA) score, and increased d-dimer levels.[3]

To date, only two retrospective case series from convenience samples from three hospitals in Wuhan, China, have been published[4] or posted on pre-print servers without peer review.[5] The most common neurological manifestations were dizziness (16.8%), headache (13.1%) and encephalopathy (2.8%). Stroke complicated COVID-19 infection in 5.9% of cases, with patients being older, with more cardiovascular comorbidities, and more severe pneumonia.[5,6]

It is yet unclear if patients with neurological disease and COVID-19 have a different neurological outcome compared to patients without COVID-19, and if this is achieved at the cost of days of hospitalization or increased mortality. Moreover, it is not known if stroke severity at admission and at discharge are similar in the two populations, and if acute phase treatments, as endovascular therapy and intravenous fibrinolysis have similar outcomes. We aim to describe the clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients with neurological disease, with and without COVID-19.

Methods

Study design and participants

This retrospective cohort study included adult inpatients (≥18 years old) from the General Neurology Unit and Vascular Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili Hospital, Brescia, Italy. This Hospital in the City of Brescia was designated as a "hub" for acute cerebrovascular diseases during the COVID-19 outbreak, in a metropolitan area of more than 1,200,000 people.[7] The original units were divided in two separate sections for patients affected (Neuro-COVID unit) and non-affected (non-COVID unit) by COVID-19, and staff neurologists were equally divided between the two units.[8]

Our study enrolled all adult inpatients who were hospitalised for neurological diseases and had a definite outcome (discharge home or to a rehabilitation facility, or death).

The criteria for discharge for patients with COVID-19 were absence of fever for at least 24 hours, a respiratory rate <22/min, and substantial improvement at chest x-ray or CT scan.

The study was approved by the local ethics committee of the ASST Spedali Civili di Brescia Hospital and the requirement for informed consent was waived by the Ethics Commission (NP 4051, approved 06.04.2020).

Data collection

Epidemiological, demographical, clinical, laboratory, treatment, and outcome data were extracted from both printed and electronic medical records using standardised anonymised data collection forms. All data were imputed and checked by four physicians (AB, AP, MG and IL). The admission data of included patients ranged from February 21 to April 5, 2020.

Laboratory procedures

SARS-CoV-2 detection in respiratory specimens were performed by real-time RT PCR methods, as described elsewhere.[9] Both nasopharyngeal and oropharyngeal swabs were performed in all

patients. If two consecutive tests obtained at least 24 hours apart resulted negative, and there was

high suspicion of COVID-19 (i.e. interstitial pneumonia at chest x-ray, low arterial partial pressure

of oxygen), a bronchoalveolar lavage was performed.

Routine blood examinations comprised complete blood count, erythrocyte sedimentation rate,

serum biochemical tests including C-reactive protein, liver and renal function, lactate

dehydrogenase, creatine kinase, high-sensitivity troponin I, serum ferritin and coagulation profile.

High sensitivity troponin I, ferritin and d-dimer were performed only in a subset of patients (~20%).

Definitions

Fever was defined as axillary temperature of at least 37.5°C. The diagnosis of delirium was defined

by the presence of features 1 and 2 and either 3 or 4 at the Confusion Assessment Method (CAM).[10]

Antiviral treatment was defined as lopinavir/ritonavir 200/50 mg 2 cp BID, darunavir 800 mg 1 cp

QD + ritonavir 100 mg 1 cp QD, or darunavir/cobicistat 800/150 mg 1 cp QD. In stroke patients, a

good outcome was defined as a modified Rankin scale (mRS) score ≤2. Instrumental exams were

defined as MRI (head), CT (head/thorax/abdomen), X-ray (thorax/abdomen), EEG, echography

(heart/neck), and Holter monitor.

Statistical analysis

Continuous and categorical variables are reported as median (interquartile range) and n (%)

respectively. Differences between patients with and without COVID-19 were compared by Mann-

Whitney U test, χ^2 test or Fisher's exact test where appropriate.

To explore the risk factors associated with in-hospital death, univariable and multivariable logistic

regression models were implemented. For multivariate analysis, to avoid overfitting in the model,

variables were chosen based on previous findings and clinical constraints.[3] Previous studies have

shown age, qSOFA scores and several laboratory findings to be associated with in-hospital

mortality. Therefore, we chose age, qSOFA scores, platelet count, C-reactive protein and lactate dehydrogenase for our multivariable logistic regression model.

The analyses were not adjusted for multiple comparisons, and given the possibility of type I error, the results should be interpreted as exploratory and descriptive.

A two-sided $p<0.05$ was considered statistically significant. Data analyses were carried out using SPSS software (version 21.0).

Data availability

All study data, including raw and analysed data, and materials will be available from the corresponding author, A.P., upon reasonable request.

Results

Two hundred fourteen adult patients were hospitalised in the Neurology and Vascular Neurology Unit of the ASST Spedali Civili di Brescia Hospital. After excluding 41 patients which were still hospitalised as of April 5, 2020, we included 173 inpatients in the final analysis. Of these, 56 (32.4%) resulted positive for COVID-19 and were admitted in the Neuro-COVID unit (see **Fig. 1**). Demographic, clinical and laboratory characteristics of included patients are reported in **Table 1**. Results are reported as median (IQR) or n (%). Compared to patients without COVID-19, patients with COVID-19 where older (77.0, IQR 67.0-83.8 vs 70.1, IQR 52.9-78.6, p=0.001), had a different distribution regarding admission diagnoses particularly for cerebrovascular disorders (n=43, 76.8% vs n=67, 57.3%, p=0.035), and had a higher qSOFA score on admission (0.52, IQR 0.0-1.0 vs 0.91 IQR 0.0-1.0, p=0.001). No significant differences were observed for comorbidities including diabetes (p=0.227), hypercholesterolemia (p=0.276), hypertension (p=0.240), coronary heart disease (p=0.212), chronic kidney disease (p=1.000) or immunodeficiency (p=1.000); malignancy rates were lower in the COVID-19 group (p=0.038). COVID-19 patients had higher in-hospital mortality (n=21, 37.5% vs n=5, 4.3%, p<0.0.001), higher incidence of delirium (n=15, 26.8% vs n=9, 7.7%, p=0.002) and fever (n=27, 48.2% vs n=14, 12.0%, p<0.0001), while days of hospitalization were similar (n=6.0 IQR 3.3-10.0 vs 5.0, IQR 4.0-8.0, p=0.353). Of patients that were discharged (excluding in-hospital deaths), days of hospitalization were increased in COVID-19 patients (8.0, IQR 5.0-11.0 vs 5.0, IQR 4.0-8.0, p=0.004).

Treatments were different between the two groups, with a wider use of high flow oxygenation (n=43, 76.8% vs n=11, 9.4%, p<0.0001), antibiotic therapy (n=36, 67.9% vs n=19, 16.2%, p<=0.0001) and antiviral treatments (n=38, 67.9% vs n=2, 1.7%, p<0.0001) in the COVID-19 group.

Laboratory analysis showed an increased neutrophil and platelet count, reduced lymphocyte count, increased C-reactive protein, erythrocyte sedimentation rate, high-sensitivity troponin I, lactate dehydrogenase, aspartate and alanine aminotransferase, prothrombin time and fibrinogen (all

p<0.05) in patients with COVID-19 compared to non-COVID-19 patients. No differences were observed for whole white blood cell count, haemoglobin, bilirubin, creatine kinase, creatinine, activated thromboplastin time, d-dimer or serum ferritin (all *p*>0.05) (see **Table 1**).

Patients with COVID-19 had a worse outcome at the mRS (5.0, IQR 2.3-6.0 vs 2.0, IQR 0.0-2.0, *p*<0.001), with similar premorbid mRS scores (1.0, IQR 1.0-2.0 vs 1.0, IQR 0.0-2.0, *p*=0.903). We observed a significant increase in cerebrovascular disease rates in the COVID-19 group (n=43, 76.8% vs n=67, 57.3%, *p*=0.018), with a similar distribution between transient ischemic attack (n=5, 11.6% vs n=8, 11.9%), ischemic stroke (n=35, 81.4% vs n=50, 74.6%) and haemorrhagic stroke (n=3, 7.0% vs n=9, 13.4%) within groups, *p*=0.560 (see **Table 2**).

Patients with ischemic stroke had similar baseline characteristics, including sex, comorbidities, premorbid mRS and National Institute of Health Stroke Scale (NIHSS) scores on admission. There were no differences in access to acute phase therapies as endovascular treatment (n=2, 5.0% vs n=8, 13.8%, *p*=0.580), intravenous fibrinolysis (n=4, 10.0% vs n=2, 3.4%, *p*=0.192) or bridging therapy (n=3, 8.6% vs n=3, 6.0%, *p*=0.687). Patients with COVID-19 had higher mRS scores at discharge (5.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0, *p*<0.0001), with a significantly lower number of patients with a good outcome (n=11, 25.6% vs n=47, 70.1%, *p*<0.0001). This difference in outcomes was also confirmed considering only patients who underwent acute phase therapies (mRS score at discharge *p*=0.004; good outcome *p*=0.027).

Moreover, patients with cerebrovascular disease and COVID-19 had an increased neutrophil and platelet count, reduced lymphocyte count, higher C-reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, aspartate and alanine aminotransferase, prothrombin time and fibrinogen levels compared to patients with cerebrovascular disease but without COVID-19 (see **Table 2**).

In univariable analysis, age, higher qSOFA scores, thrombocytopenia, elevated C-reactive protein and lactate dehydrogenase were associated with in-hospital death in the COVID-19 group (**Table 3**). In the multivariable logistic regression model, we found that higher qSOFA scores (odds ratio 4.47, 95% CI 1.21-16.50; *p*=0.025), lower platelets (0.98, 0.97-0.99; *p*=0.005) and higher lactate

dehydrogenase (1.01, 1.00-1.03; *p*=0.009) on admission were all associated with increased odds of

death in COVID-19 patients (**Table 3**).

Discussion

This retrospective cohort study identified several differences between patients with and without COVID-19 who were hospitalised with a neurological disease. In particular, patients with COVID-19 were older, had higher qSOFA scores on admission, and had a higher rate of cerebrovascular disorders compared to patients without COVID-19. During hospitalization, COVID-19 patients had a higher incidence of delirium and fever, with prolonged hospital length of stay and increased in-hospital mortality rates. Additionally, patients with COVID-19 had significant differences in laboratory values on admission, including blood count analysis, acute phase proteins and coagulation profiles.

We identified potential risk factors for a poor prognosis at an early stage, as high qSOFA score, thrombocytopenia and increased lactate dehydrogenase levels. Previous reports have also found that SOFA and qSOFA scores were associated with in-hospital mortality, as well as d-dimer and older age, in adult inpatients with COVID-19.[3] The qSOFA is a bedside prompt scale that may identify patients with suspected infection who are at greater risk for a poor outcome outside the intensive care unit, and may be rapidly performed by the clinician without the need of laboratory analysis.[11] Interestingly, we observed a significant increase of stroke rates in patients with COVID-19, with worse outcomes compared to the non-COVID-19 group, including higher mRS scores at discharge and a significantly lower number of patients with a good outcome, at par with access to acute phase therapies. As recently suggested in a statement by the American Heart Association and by the American Stroke Association (AHA/ASA) Stroke Council Leadership, stroke mechanisms in COVID-19 could include different processes, including the release of pro-inflammatory cytokines with a direct effect on plaque rupture through local inflammation and activation of coagulation factors, or cardioembolism from virus-related cardiac injury.[12–16]

Moreover, a direct effect of the virus on endothelial cells or on heart tissue could be hypothesized, considering that the receptor for SARS-CoV-2, the angiotensin converting enzyme 2,[17–19] is expressed on vascular endothelial cells and myocytes.[20–22]

In our cohort we observed several indexes of an altered coagulability in patients with COVID-19 compared to patients without COVID-19. Prothrombin time and d-dimer were increased in the former group, including inflammatory indexes as C-reactive protein and erythrocyte sedimentation rate. This marker profile is consistent with what has been observed in disseminated intravascular coagulation and may play an important role in stroke incidence and severity in COVID-19 patients.[23] Abnormal coagulation parameters have been also shown to be associated with poor prognosis in patients with COVID-19 associated pneumonia.[24]

From the present analysis, patients who underwent endovascular therapy or intravenous fibrinolysis in the COVID-19 group had more severe outcomes, including increase in NIHSS and mRS scores at discharge. This raises a critical issue if patients with COVID-19 should be equally treated with acute phase therapies; further studies on broader populations should try to shed further light on this matter.

With the surge of intensive care unit admissions during the pandemic,[2] and as underlined by the AHA/ASA Stroke Council Leadership, it has become necessary to prioritize intensive care unit resources, at the possible expenses of stroke patients,[14,25] withholding ventilation when necessary and raising issues on potential legal liabilities.[26] These aspects should all be addressed in neurology units that deal with acute phase diseases and COVID-19 patients.

We acknowledge that this study entails some limitations. First, due to the retrospective study design, not all laboratory tests were performed in all patients, including high sensitivity troponin I, ferritin and d-dimer, therefore their role could have not been thoroughly assessed in this study. Second, results on stroke do not take into account several factors due to the retrospective design, including stroke subtypes, infarct volume and recanalization rates. Third, interpretation of our findings could be limited by sample size and by the single-centre design.

To the best of our knowledge, this is the largest retrospective cohort study among patients with neurological disorders and COVID-19, with a definite outcome. Patients with COVID-19 and

neurological disease have worse clinical and neurological outcomes, with higher in-hospital

mortality rates compared to patients without COVID-19.

Acknowledgments

We would like to express our gratitude to the nurses, auxiliary staff, technicians and all the colleagues who collaborated for the management of patients during the COVID-19 outbreak. Moreover, we would like to thank Dr. Marco Trivelli, Dr. Camilo Rossi and Dr. Loretta Jacquot for their support in setting up a Neuro-COVID Unit.

Author contributions

Conception and design of the study: AB, AP, EP, BB and AP. Acquisition and analysis of data: AB, AP, EP, AP, MG, IL, CA, AA, EB, SB, LB, SC, MC, AC, SCP, EC, VC, ID, MG, SG, NG, SG, AI, LP, PL, UL, ML, SM, FS, RR, BR, LR, AS, RS, VV, IV, NZ, BB, MM and AP. Drafting the manuscript and figures: AB, AP, EP and AP.

Declaration of interests

The authors declare no competing interests.

Disclosures

A. Benussi, A. Pilotto, E. Premi, I. Libri, M. Giunta, C. Agosti, A. Alberici, E. Baldelli, M. Benini, S. Bonacina, L. Brambilla, S. Caratozzolo, M. Cortinovis, A. Costa, S. Cotti Piccinelli, E. Cottini, V. Cristillo, I. Delrio, M. Gamba, S. Gazzina, N. Gilberti, S. Gipponi, A. Imarisio, P. Invernizzi, U. Leggio, M. Leonardi, P. Liberini, M. Locatelli, S. Masciocchi, L. Poli, R. Rao, B. Risi, L. Rozzini, A. Scalvini, F. Schiano di Cola, R. Spezi, V. Vergani, I. Volonghi, N. Zoppi, B. Borroni, M. Magoni, A. Pezzini report no disclosures relevant to the manuscript. A. Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals.

References

Protezione Civile: Coronavirus. http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus.

Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. *JAMA* 2020; **19**: 2–3.

Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.

Mao L, Jin H, Wang M, *et al.* Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020. DOI:10.1001/jamaneurol.2020.1127.

Li Y, Wang M, Zhou Y, *et al.* Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. *SSRN Electron J* 2020; **19**. DOI:10.2139/ssrn.3550025.

Mao L, Wang M, Chen S, *et al.* Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. *medRxiv* 2020; : 2020.02.22.20026500.

Dato Istat - Popolazione residente al 1° gennaio 2019 nella provincia di Brescia. http://demo.istat.it/bilmens2019gen/index.html.

COVID-19: Neurologists in Italy to Colleagues in US: Look for Poorly-Defined Neurologic Conditions in Patients with the Coronavirus. https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=920.

Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.

Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med* 1990; **113**: 941–8.

Seymour CW, Liu VX, Iwashyna TJ, *et al.* Assessment of clinical criteria for sepsis for the third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA - J Am Med Assoc* 2016; **315**: 762–74.

Guo T, Fan Y, Chen M, *et al.* Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **2019**. DOI:10.1001/jamacardio.2020.1017.

Inciardi RM, Lupi L, Zaccone G, *et al.* Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **2019**: 4–9.

Lyden P. Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic. *Stroke* 2020; **53**: STROKEAHA.120.030023.

Davidson JA, Warren-Gash C. Cardiovascular complications of acute respiratory infections: current research and future directions. *Expert Rev Anti Infect Ther* 2019; **17**: 939–42.

Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med* 2004; **351**: 2611–8.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* 2020; **2**: 1444–8.

Shang J, Ye G, Shi K, *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature* 2020; : 1–8.

Lan J, Ge J, Yu J, *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020; : 1–20.

Mendoza Torres E, Oyarzún A, Mondaca Ruff D, *et al.* ACE2 and vasoactive peptides: Novel players in cardiovascular/renal remodeling and hypertension. *Ther Adv Cardiovasc Dis* 2015; **9**: 217–37.

Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**: 631–7.

Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. *Am J Physiol - Hear Circ Physiol* 2008; **295**: 2373–9.

Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. *Br J Haematol* 2009; **145**: 24–33.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; : 844–7.

White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic. *JAMA* 2020; **146**: e61S-e74S.

Cohen IG, Crespo AM, White DB. Potential Legal Liability for Withdrawing or Withholding Ventilators During COVID-19: Assessing the Risks and Identifying Needed Reforms. *JAMA* 2020; : 3–4.

Table 1. Demographic, clinical, laboratory characteristics, treatment and clinical outcomes of all included patients.

	Total (n=173)	non-COVID-19 (n=117)	COVID-19 (n=56)	*p* value
Demographic and clinical characteristics				
Age, years	72.3 (57.5-80.5)	70.1 (52.9-78.6)	77.0 (67.0-83.8)	0.001
Sex				0.518
Female	80 (46.2%)	52 (44.4%)	28 (50.0%)	
Male	93 (53.8%)	65 (55.6%)	28 (50.0%)	
Current smoker	8 (4.6%)	7 (6.0%)	1 (1.8%)	0.440
Comorbidity				
Diabetes	34 (19.7%)	20 (17.1%)	14 (25.0%)	0.227
Hypercholesterolemia	47 (27.2%)	35 (29.9%)	12 (21.4%)	0.276
Hypertension	108 (62.4%)	77 (65.8%)	31 (55.4%)	0.240
Coronary heart disease	20 (11.6%)	11 (9.4%)	9 (16.1%)	0.212
Malignancy	43 (24.9%)	35 (29.9%)	8 (14.3%)	0.038
Chronic Kidney Disease	7 (4.0%)	5 (4.3%)	2 (3.6%)	1.000
Immunodeficiency	5 (2.9%)	4 (3.4%)	1 (1.8%)	1.000
qSOFA score	0.65 (0.0-1.0)	0.52 (0.0-1.0)	0.91 (0.0-1.0)	0.001
Neurological diagnosis				0.035
Cerebrovascular disease	110 (63.6%)	67 (57.3%)	43 (76.8%)	
Epilepsy	23 (13.3%)	19 (16.2%)	4 (7.1%)	
Inflammatory/Infectious disease	9 (5.2%)	9 (7.7%)	0 (0.0%)	
Neoplastic	3 (1.7%)	3 (2.6%)	0 (0.0%)	
Other	28 (16.2%)	19 (16.2%)	9 (16.1%)	
Laboratory findings				
White-cell count (mm^3)	8.4 (6.6-10.6)	8.2 (6.6-10.5)	8.7 (6.7-12.9)	0.264
Neutrophil count (mm^3)	5.9 (4.1-8.2)	3.9 (5.5-8.1)	7.1 (4.9-9.4)	0.014
Lymphocyte count (mm^3)	1.4 (1.0-1.9)	1.6 (1.2-2.1)	1.0 (0.8-1.4)	<0.0001
Platelet count (mm^3)	228.0 (290.5)	215.0 (175.0-266.0)	262.6 (191.8-311.8)	0.011
Haemoglobin (g/dl)	13.3 (11.9-14.5)	13.2 (11.8-14.5)	13.4 (12.2-14.7)	0.284
C-reactive protein (mg/L)	7.4 (1.8-32.4)	5.3 (1.2-14.9)	28.9 (4.5-70.5)	<0.0001
Erythrocyte sedimentation rate (mm/1h)	25.0 (9.5-31.0)	20.0 (13.-31.3)	53.5 (30.0-84.8)	<0.0001
High-sensitivity troponin I, pg/mL	16.0 (9.5-31.0)	14.5 (14.5-19.8)	27.0 (13.0-41.0)	0.007
Lactate dehydrogenase (U/L)	204.9 (168.0-296.5)	161 (184-214)	275.7 (232.5-368-5)	<0.0001
Aspartate aminotransferase (U/L)	26.0 (21.0-38.0)	24.0 (20.0-32.0)	37.5 (24.5-60.8)	<0.0001
Alanine aminotransferase (U/L)	24.0 (17.0-36.0)	22.0 (15.5-31.0)	32.5 (20.0-43.2)	<0.0001
Total bilirubin (μmol/L)	0.60 (0.47-0.85)	0.60 (0.47-0.83)	0.60 (0.46-0.98)	0.561
Creatine kinase (U/L)	112.0 (65.0-251.5)	109.0 (64.5-237.5)	117 (65.8-343.0)	0.230

Creatinine (µmol/L)	0.91 (0.77-1.10)	0.91 (0.76-1.1)	0.77 (0.94-1.1)	0.454
Prothrombin time (sec)	11.8 (12.3-13.3)	12.2 (11.6-12.9)	12.7 (12.1-15.2)	0.002
Activated thromboplastin time (sec)	29.3 (27.3-31.2)	29.3 (27.5-31.3)	29.4 (27.3-31.1)	0.959
D-dimer (mg/L)	680.5 (313.3-2239.5)	321.5 (228.0-1019.5)	735.5 (329.8 -2710.5)	0.195
Fibrinogen (mg/dL)	348.4 (298.5-461.1)	321.0 (288.5-376.1)	484.0 (376.3-600.3)	<0.0001
Serum ferritin (µg/L)	377.0 (173.5-706.5)	155.0 (66.5-340.25)	392.0 (194.5-827.0)	0.075
Treatments and exams				
Antibiotic treatment	55 (31.8%)	19 (16.2%)	36 (64.3%)	<0.0001
Antiviral treatment	40 (23.1%)	2 (1.7%)	38 (67.9%)	<0.0001
High-flow oxygen therapy	54 (31.2%)	11 (9.4%)	43 (76.8%)	<0.0001
Instrumental exams, n	5.0 (4.0-7.0)	5.0 (3.0-7.0)	5.0 (4.0-8.0)	0.553
Outcomes				
In hospital mortality	26 (15.0%)	5 (4.3%)	21 (37.5%)	<0.0001
Incident delirium	24 (13.9%)	9 (7.7%)	15 (26.8%)	0.002
Fever during hospitalization	41 (23.7%)	14 (12.0%)	27 (48.2%)	<0.0001
Hospital length of stay, days	5.0 (4.0-8.0)	5.0 (4.0-8.0)	6.0 (3.3-10.0)	0.353
Modified Rankin Scale premorbid	1.0 (0.0-2.0)	1.0 (0.0-2.0)	1.0 (1.0-2.0)	0.903
Modified Rankin Scale discharge	2.0 (1.0-4.0)	2.0 (1.0-3.0)	5.0 (2.3-6.0)	<0.0001

Data are median (IQR), or n (%). *p* values were calculated by Mann-Whitney U test, χ^2 test or Fisher's exact test, as appropriate. qSOFA=quick Sequential Organ Failure Assessment.

Table 2. Demographic, clinical, laboratory characteristics, treatment and clinical outcomes of patients with cerebrovascular disease.

	Total (n=110)	non-COVID-19 (n=67)	COVID-19 (n=43)	*p* value
Cerebrovascular event				0.560
Transient ischemic attack	13 (11.8%)	8 (11.9%)	5 (11.6%)	
Ischemic stroke	85 (77.2%)	50 (74.6%)	35 (81.4%)	
Haemorrhagic stroke	12 (10.9%)	9 (13.4%)	3 (7.0%)	
Demographic and clinical characteristics				
Age, years	76.2 (61.4-82.5)	74.7 (58.1-80.6)	76.9 (66.8-85.2)	0.037
Sex				0.556
Female	49 (44.5%)	28 (41.8%)	21 (48.8%)	
Male	61 (55.5%)	22 (51.2%)	39 (58.2%)	
Current smoker	7 (6.4%)	6 (9.0%)	1 (2.3%)	0.243
Comorbidity				
Diabetes	23 (20.9%)	13 (19.4%)	10 (23.3%)	0.639
Hypercholesterolemia	33 (30.0%)	23 (34.3%)	10 (23.3%)	0.287
Hypertension	76 (69.1%)	50 (74.6%)	26 (60.5%)	0.141
Coronary heart disease	16 (14.5%)	8 (11.9%)	8 (18.6%)	0.409
Malignancy	23 (20.9%)	18 (26.9%)	5 (11.6%)	0.060
Chronic Kidney Disease	5 (4.5%)	3 (4.5%)	2 (4.7%)	1.000
Immunodeficiency	4 (3.6%)	3 (4.5%)	1 (2.3%)	1.000
qSOFA score	0.68 (0.0-1.0)	0.54 (0.0-1.0)	0.91 (0.0-1.0)	0.007
Laboratory findings				
White-cell count (mm^3)	8.5 (6.6-10.6)	8.3 (6.6-10.5)	8.9 (6.7-11.7)	0.357
Neutrophil count (mm^3)	6.1 (4.4-8.6)	5.6 (4.1-8.2)	7.3 (5.0-9.6)	0.036
Lymphocyte count (mm^3)	1.3 (0.9-1.8)	1.5 (1.2-2.1)	1.0 (0.8-1.4)	<0.0001
Platelet count (mm^3)	230.5 (180.0-294.8)	210.0 (174.0-265.0)	276.0 (197.0-315.0)	0.017
Haemoglobin (g/dl)	13.1 (11.5-14.6)	12.7 (11.5-14.2)	13.4 (12.1-14.9)	0.091
C-reactive protein (mg/L)	7.6 (2.0-35.9)	5.1 (1.5-12.9)	28.0 (4.4-71.1)	<0.0001
Erythrocyte sedimentation rate (mm/1h)	25.0 (14.0-50.5)	20.0 (12.0-31.0)	49.0 (29.3-85.0)	<0.001
High-sensitivity troponin I, pg/mL	16.0 (10.0-29.0)	16.0 (9.3-21.3)	27.0 (10.0-41.0)	0.039
Lactate dehydrogenase (U/L)	221.0 (168.0-277.5)	156.0 (178.0-222.0)	277.7 (239.0-365.0)	<0.0001
Aspartate aminotransferase (U/L)	27.4 (21.0-37.3)	24.0 (21.0-29.0)	36.0 (28.0-52.0)	<0.0001
Alanine aminotransferase (U/L)	24.0 (16.0-34.3)	20.0 (15.0-27.0)	31.0 (20.0-40.7)	<0.0001
Total bilirubin (μmol/L)	0.64 (0.48-0.94)	0.63 (0.48-0.91)	0.66 (0.48-1.0)	0.349
Creatine kinase (U/L)	108.0 (66.0-244.0)	103.0 (65.0-222.0)	114.0 (69.0-337.0)	0.325
Creatinine (μmol/L)	0.95 (0.77-1.12)	0.94 (0.76-1.14)	0.95 (0.77-1.11)	0.864
Prothrombin time (sec)	12.5 (12.0-14.1)	12.4 (11.9-13.0)	12.8 (12.2-15.6)	0.012

Activated thromboplastin time (sec)	29.0 (26.8-31.0)	29.1 (26.7-31.5)	28.6 (27.3-30.7)	0.729
D-dimer (mg/L)	735.5 (339.3-2882.3)	686.0 (317.0-686.0)	735.5 (364.3-2910.8)	0.560
Fibrinogen (mg/dL)	350.8 (290.6-466.0)	312.0 (258.0-384.4)	471.0 (368.0-545.0)	<0.0001
Serum ferritin (µg/L)	411.0 (244.0-739.0)	152.0 (38.0-152.0)	452.5 (268.0-871.0)	0.082
Treatments and exams				
Antibiotic treatment	39 (35.5%)	11 (16.4%)	28 (65.1%)	<0.0001
Antiviral treatment	27 (25.5%)	0 (0.0%)	27 (62.8%)	<0.0001
High-flow oxygen therapy	40 (36.4%)	7 (10.4%)	33 (76.7%)	<0.0001
Instrumental exams, n	6.0 (4.5-8.0)	6.0 (5.0-8.0)	6.0 (4.0-8.0)	0.633
Acute phase therapies (ischemic stroke only)	22 (25.9%)	13 (26.0%)	9 (25.7%)	1.000
Intravenous fibrinolysis	6 (6.1%)	2 (3.4%)	4 (10.0%)	0.192
Endovascular therapy	10 (10.2%)	8 (13.8%)	2 (5.0%)	0.580
Bridging therapy	6 (7.1%)	3 (6.0%)	3 (8.6%)	0.687
Outcomes				
In hospital mortality	19 (17.3%)	4 (6.0%)	15 (34.9%)	<0.0001
Incident delirium	13 (11.8%)	4 (6.0%)	9 (20.9%)	0.031
Fever during hospitalization	29 (26.4%)	8 (11.9%)	21 (48.8%)	<0.0001
Hospital length of stay, days	5.0 (4.0-8.0)	5.0 (4.0-8.0)	6.0 (4.0-9.0)	0.378
Modified Rankin Scale premorbid	1.0 (0.0-2.0)	1.0 (0.0-2.0)	1.0 (0.0-1.0)	0.727
Modified Rankin Scale discharge	2.0 (1.0-5.0)	2.0 (1.0-3.0)	5.0 (2.0-6.0)	<0.0001
Good outcome	58 (52.7%)	47 (70.1%)	11 (25.6%)	<0.0001
NIH Stroke Scale admission	6.0 (4.5-8.0)	6.0 (5.0-8.0)	10.0 (3.0-15.0)	0.114
NIH Stroke Scale discharge	5.0 (2.0-15.0)	4.0 (2.0-15.0)	9.0 (1.0-19.0)	0.003

Data are median (IQR), or n (%). *p* values were calculated by Mann-Whitney U test, χ^2 test or Fisher's exact test, as appropriate. qSOFA=quick Sequential Organ Failure Assessment; combined therapy=intravenous fibrinolysis followed by endovascular therapy

Table 3. Risk factors on admission associated with in-hospital mortality in COVID-19 patients.

	Univariable OR (95% CI)	*p* value	Multivariable OR (95% CI)	*p* value
Demographic and clinical characteristics				
Age, years	1.06 (1.00-1.12)	0.043	1.08 (0.99-1.18)	0.090
Female sex (vs male)	0.11 (0.11-1.03)	0.057		
Current smoker (vs non-smoker)	0.000	1.000		
Comorbidity present (vs non-present)				
Diabetes	0.36 (0.09-1.50)	0.161		
Hypercholesterolemia	0.48 (0.11-2.03)	0.319		
Hypertension	0.32 (0.10-0.99)	0.048		
Coronary heart disease	0.81 (0.18-3.63)	0.778		
Malignancy	1.00 (0.21-4.69)	1.000		
Chronic Kidney Disease	1.70 (0.10-28.70)	0.713		
Immunodeficiency	0.000	1.000		
qSOFA score	5.12 (1.77-14.83)	0.003	4.47 (1.21-16.50)	0.025
Laboratory findings				
White-cell count (mm^3)	1.02 (0.93-1.11)	0.730		
Neutrophil count (mm^3)	1.02 (0.93-1.13)	0.651		
Lymphocyte count (mm^3)	0.45 (0.13-1.50)	0.192		
Platelet count per (mm^3)	0.99 (0.98-0.99)	0.012	0.98 (0.97-0.99)	0.005
Haemoglobin (g/dl)	1.18 (0.86-1.61)	0.303		
C-reactive protein (mg/L)	1.01 (1.00-1.02)	0.031	1.00 (0.99-1.01)	0.981
Erythrocyte sedimentation rate (mm/1h)	1.01 (0.99-1.03)	0.460		
High-sensitivity troponin I, pg/mL	1.03 (1.00-1.07)	0.078		
Lactate dehydrogenase (U/L)	1.01 (1.00-1.02)	0.004	1.01 (1.00-1.03)	0.009
Aspartate aminotransferase (U/L)	1.02 (1.00-1.03)	0.112		
Alanine aminotransferase (U/L)	1.00 (0.99-1.02)	0.599		
Total bilirubin (μmol/L)	0.79 (0.31-2.03)	0.630		
Creatine kinase (U/L)	1.00 (1.00-1.00)	0.080		
Creatinine (μmol/L)	4.71 (0.88-25.3)	0.071		
Prothrombin time (sec)	1.07 (0.96-1.20)	0.210		
Activated thromboplastin time (sec)	1.02 (0.91-1.15)	0.682		
D-dimer (mg/L)	1.00 (1.00-1.00)	0.058		
Fibrinogen (mg/dL)	1.00 (1.00-1.01)	0.108		
Serum ferritin (μg/L)	1.00 (1.00-1.00)	0.773		

OR=odds ratio; qSOFA=quick Sequential Organ Failure Assessment.

Legend to figure.

Figure 1. Weekly admissions of patients with neurological diseases, with and without COVID-19.